These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

585 related items for PubMed ID: 11410853

  • 1. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.
    Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M.
    Biotechnol Bioeng; 2001 Aug 20; 74(4):288-94. PubMed ID: 11410853
    [Abstract] [Full Text] [Related]

  • 2. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
    Ferrara C, Brünker P, Suter T, Moser S, Püntener U, Umaña P.
    Biotechnol Bioeng; 2006 Apr 05; 93(5):851-61. PubMed ID: 16435400
    [Abstract] [Full Text] [Related]

  • 3. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, Shitara K, Satoh M.
    Biotechnol Bioeng; 2004 Sep 05; 87(5):614-22. PubMed ID: 15352059
    [Abstract] [Full Text] [Related]

  • 4. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity.
    Kumpel BM, Rademacher TW, Rook GA, Williams PJ, Wilson IB.
    Hum Antibodies Hybridomas; 1994 Sep 05; 5(3-4):143-51. PubMed ID: 7756579
    [Abstract] [Full Text] [Related]

  • 5. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.
    Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE.
    Nat Biotechnol; 1999 Feb 05; 17(2):176-80. PubMed ID: 10052355
    [Abstract] [Full Text] [Related]

  • 6. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M.
    Glycobiology; 2007 Jan 05; 17(1):104-18. PubMed ID: 17012310
    [Abstract] [Full Text] [Related]

  • 7. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
    Shibata-Koyama M, Iida S, Okazaki A, Mori K, Kitajima-Miyama K, Saitou S, Kakita S, Kanda Y, Shitara K, Kato K, Satoh M.
    Glycobiology; 2009 Feb 05; 19(2):126-34. PubMed ID: 18952826
    [Abstract] [Full Text] [Related]

  • 8. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
    Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M.
    Clin Cancer Res; 2006 May 01; 12(9):2879-87. PubMed ID: 16675584
    [Abstract] [Full Text] [Related]

  • 9. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, Hong K, Truong BT, Ng D, Shen A, Nakamura G, Gong Q, Presta LG, Beresini M, Kelley B, Lowman H, Wong WL, Meng YG.
    J Immunol Methods; 2011 Feb 28; 365(1-2):132-41. PubMed ID: 21185301
    [Abstract] [Full Text] [Related]

  • 10. Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies.
    Barbin K, Stieglmaier J, Saul D, Stieglmaier K, Stockmeyer B, Pfeiffer M, Lang P, Fey GH.
    J Immunother; 2006 Feb 28; 29(2):122-33. PubMed ID: 16531813
    [Abstract] [Full Text] [Related]

  • 11. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
    Wright A, Morrison SL.
    J Immunol; 1998 Apr 01; 160(7):3393-402. PubMed ID: 9531299
    [Abstract] [Full Text] [Related]

  • 12. Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.
    Nagashima H, Tezuka T, Tsuchida W, Maeda H, Kohroki J, Masuho Y.
    Mol Immunol; 2008 May 01; 45(10):2752-63. PubMed ID: 18353438
    [Abstract] [Full Text] [Related]

  • 13. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.
    J Immunol Methods; 2011 Oct 28; 373(1-2):67-78. PubMed ID: 21855548
    [Abstract] [Full Text] [Related]

  • 14. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
    Hodoniczky J, Zheng YZ, James DC.
    Biotechnol Prog; 2005 Oct 28; 21(6):1644-52. PubMed ID: 16321047
    [Abstract] [Full Text] [Related]

  • 15. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
    Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, Satoh M, Shitara K.
    J Immunol Methods; 2005 Nov 30; 306(1-2):151-60. PubMed ID: 16219319
    [Abstract] [Full Text] [Related]

  • 16. Engineering novel Lec1 glycosylation mutants in CHO-DUKX cells: molecular insights and effector modulation of N-acetylglucosaminyltransferase I.
    Zhong X, Cooley C, Seth N, Juo ZS, Presman E, Resendes N, Kumar R, Allen M, Mosyak L, Stahl M, Somers W, Kriz R.
    Biotechnol Bioeng; 2012 Jul 30; 109(7):1723-34. PubMed ID: 22252477
    [Abstract] [Full Text] [Related]

  • 17. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering.
    Schuster M, Umana P, Ferrara C, Brünker P, Gerdes C, Waxenecker G, Wiederkum S, Schwager C, Loibner H, Himmler G, Mudde GC.
    Cancer Res; 2005 Sep 01; 65(17):7934-41. PubMed ID: 16140965
    [Abstract] [Full Text] [Related]

  • 18. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
    Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6248-55. PubMed ID: 15448014
    [Abstract] [Full Text] [Related]

  • 19. Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding.
    Armour KL, Smith CS, Clark MR.
    J Immunol Methods; 2010 Mar 31; 354(1-2):20-33. PubMed ID: 20138184
    [Abstract] [Full Text] [Related]

  • 20. Development of an ELISA based bridging assay as a surrogate measure of ADCC.
    Miller AS, Tejada ML, Gazzano-Santoro H.
    J Immunol Methods; 2012 Nov 30; 385(1-2):45-50. PubMed ID: 22914441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.